Encompass Health (NYSE:EHC – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Monday, August 1st. Analysts expect Encompass Health to post earnings of $0.97 per share for the quarter. Encompass Health has set its FY22 guidance at $3.83-4.19 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.
Encompass Health (NYSE:EHC – Get Rating) last issued its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Encompass Health had a net margin of 7.51% and a return on equity of 17.99%. The firm had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the firm earned $1.05 earnings per share. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, analysts expect Encompass Health to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Encompass Health Trading Up 1.6 %
Ad Investing Trends
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
Shares of EHC opened at $49.99 on Monday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26. The company has a market cap of $4.99 billion, a price-to-earnings ratio of 12.79, a PEG ratio of 1.80 and a beta of 1.00. The stock has a fifty day moving average price of $56.58 and a two-hundred day moving average price of $63.54. Encompass Health has a 52-week low of $44.33 and a 52-week high of $85.75.
Encompass Health Cuts Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 17th. Shareholders of record on Monday, October 3rd will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Friday, September 30th. Encompass Health’s dividend payout ratio is currently 28.64%.
Analysts Set New Price Targets
EHC has been the topic of a number of research reports. Credit Suisse Group reduced their target price on shares of Encompass Health from $83.00 to $82.00 and set an “outperform” rating on the stock in a research report on Friday, June 10th. Raymond James reduced their target price on shares of Encompass Health from $85.00 to $70.00 in a research report on Friday, June 17th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Monday, July 4th. Truist Financial reduced their target price on shares of Encompass Health from $85.00 to $75.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. Finally, TheStreet lowered shares of Encompass Health from a “b-” rating to a “c+” rating in a report on Tuesday, June 28th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Encompass Health has a consensus rating of “Buy” and a consensus price target of $79.56.
Insider Transactions at Encompass Health
In related news, Director Kevin J. O’connor acquired 1,000 shares of the stock in a transaction dated Friday, May 6th. The stock was bought at an average price of $66.48 per share, with a total value of $66,480.00. Following the completion of the transaction, the director now directly owns 3,436 shares of the company’s stock, valued at $228,425.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by insiders.
Institutional Investors Weigh In On Encompass Health
Several large investors have recently made changes to their positions in the stock. US Bancorp DE grew its position in Encompass Health by 66.4% in the first quarter. US Bancorp DE now owns 9,336 shares of the company’s stock valued at $664,000 after purchasing an additional 3,725 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Encompass Health in the first quarter valued at $318,000. PNC Financial Services Group Inc. lifted its stake in Encompass Health by 10.5% in the first quarter. PNC Financial Services Group Inc. now owns 8,750 shares of the company’s stock valued at $622,000 after acquiring an additional 834 shares during the last quarter. Bank of Montreal Can lifted its stake in Encompass Health by 1.5% in the first quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock valued at $806,000 after acquiring an additional 173 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Encompass Health by 10.5% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,463 shares of the company’s stock valued at $2,593,000 after acquiring an additional 3,477 shares during the last quarter. Institutional investors own 91.70% of the company’s stock.
About Encompass Health
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Encompass Health right now?
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
